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 Summary
 Background:  ATRA Syndrome appears as a side effect of acute promyelocytic leukemia treatment with ATRA, 
vitamin A derivative. The etiopathogenesis of the syndrome remains unclear. Fever, generalized 
edema, pleural or pericardial effusion, respiratory distress, coagulation disorders and sometimes 
renal failure are the most common clinical symptoms of ATRAS. Radiological features of the 
syndrome are very diverse. Early diagnosis followed by introduction of appropriate treatment 
(corticosteroids) prevents worsening of the patients’ condition and significantly reduces the risk of 
death. Although clinical symptomatology of ATRAS has been widely described, there are still few 
descriptions of its radiological manifestation.
 Case report:  A 53-year-old female was referred to the Hematology Department for further detailed diagnostics 
and appropriate therapy from the district hospital, where she had been primarily admitted due to 
weakness, easy fatigue, loss of appetite and blood extravasations on the skin of the extremities. The 
patient’s general condition on admission was assessed as quite good. Acute promyelocytic leukemia 
(AML M3 according to FAB classification) was diagnosed. The introduced treatment included 
ATRA. On the second day of treatment, the patient developed fever, dyspnea, generalized edema, 
and coagulation disorders increased. Chest X-ray findings reminded ARDS. The diagnosis of ATRAS 
was established, which resulted in ATRA withdrawal. After administration of corticosteroids, the 
patient’s condition improved gradually within a few days. ATRA was reintroduced then, since the 
signs of leukemia had intensified. The patient remains in charge of the Hematology Department. 
 Conclusions:  Changes of chest X-ray pictures in AML patients treated with ATRA should be interpreted in clinical 
context due to lack of radiological features specific for ATRAS.
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Background
ATRA Syndrome (All-Trans-Retinoic Acid Syndrome, ATRAS) 
develops as a complication associated with treatment of 
some myeloproliferative diseases with ATRA, a vitamin 
A derivative, which is a physiological component of plasma. 
Administered to patients with acute promyelocytic leuke-
mia (M3 according to FAB classification), ATRA stimulates 
the process of promyelocytic differentiation into mature 
granulocytes. 
Etiopathogenesis of the syndrome, described for the first 
time by Frankel et al. in 1992, has not been  elucidated 
equivocally [1, 2, 3]. According to Dubois et al. [4, 5] 
and Gentile et al. [6], increased secretion of cytokines 
(IL-1beta, Il-6, Il-8 or TNF-alpha) in the process of ATRA-
induced differentiation of promyelocytes may play a role 
here. Another hypothesis presumes that promyelocytes 
differentiated as a result of treatment with ATRA, despite 
some properties characteristic of neutrophils (e.g. migra-
tion to tissues), remain in other respects functionally 
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immature, which may lead to some organic abnormali-
ties observed in the course of ATRAS [7, 8, 9, 10]. Some 
researchers emphasize also the role of integrins (leuko-
cytic adhesion receptors) in the mechanism of endothelial 
damage. ATRA increases the expression of genes encoding 
these receptors [3, 7, 11].
Characteristic symptoms of ATRAS include: fever of unclear 
etiology, body mass increase due to excessive fluid accu-
mulation in the exctavascular space, transudates to the 
cavities of the body (especially the pleural cavity and the 
pericardium), respiratory problems, abnormalities of the 
coagulation system, diffuse bleeding, and sometimes also 
the signs of renal insufficiency. 
The radiological presentations of ATRAS are character-
ized by a wide variety of abnormalities: enlarged heart 
contour (increased cardiopulmonary index), enhanced 
vascular markings, signs of congestion, interlobar fissure 
 widening due to fluid transudation present in the pleura, 
air bronchogram. The pulmonary interstitial abnormalities, 
may appear in the form resembling frosted glass, densi-
ties or nodular pattern. Sometimes bronchial wall thicken-
ing is noted. The aforementioned changes resemble those 
observed in acute pulmonary edema or ARDS. 
Although the complication is infrequent, numerous symp-
toms and sometimes dramatic clinical course require inten-
sive therapy. As indicated by the literature data, early diag-
nosis and prompt institution of treatment (corticosteroids, 
oxygen therapy) prevents progression of  organic dysfunc-
tions and significantly reduces the risk of fatal outcome.
The clinical symptomatology of ATRAS has been described 
extensively in available literature. However, reports con-
cerning radiological manifestations of this syndrome are 
scarce [7, 12, 13].
Case report
A 53-year-old female patient was referred for  extended 
diagnostics and treatment to the MUG Hematology 
Department from the Municipal Hospital in Gdynia, where 
she had been admitted because of weakness, easy fatigue, 
loss of appetite and effusions on the extremities.
Eight years before, the patient had been diagnosed with 
type 2 diabetes, treated subsequently with oral hypoglyc-
emizing agents (Metformin). She had also been treated for 
arterial hypertension (Enarenal, Amlozek) for a few years. 
She was also suffering from glaucoma and had occasionally 
taken medication for osteoarthrosis during the last 3 years 
preceding hospitalization.
The patient’s general condition on admission to the 
Hematology Department was assessed as quite good. On 
physical examination, overweight, leucoderma, blood 
extravasations on distal parts of the extremities, as well 
as signs of dehydration were observed. Laboratory investi-
gations revealed anemia (hemoglobin level (Hb) – 8.8 g/dl), 
increased lekocytosis (leukocytes (WBC) – 48 g/l), thrombo-
cytopenia (blood platelets (PLT) 22g/l), abnormal coagula-
tion system parameters (increased D-dimers level, decrease 
of kaolin-kephalin time, prothrombin index and fibrinogen) 
and hyperglycemia (glucose – 358 mg/dl). On the basis of 
overall clinical presentation, including blood cell count, 
immunophenotyping, cytochemical and cytogenetic investi-
gations of the bone marrow, acute promyelocytic leukemia 
(AML M3 according to FAB) was diagnosed.
The treatment was instituted: Vesanoid, Cyclonamine, 
platelet mass. In order to compensate the glycemia level, 
a short-lasting insulin preparation and Mixtard 30 insu-
lin was introduced in addition to Metformin. The patient 
received also Omeprazole and rehydrating fluids. On the 
second day, daunorubicin and Zofran were added. Fresh 
frozen plasma transfusion was also given to the patient.
On the third day of hospitalization, the patient developed 
fever (39.6ºC) with significant dyspnea. Physical exami-
nation revealed bilaterally reduced vesicular murmur 
in the lower 2/3 of the lungs, which was accompanied 
by numerous crepitant rales on auscultation. The heart 
rate was regular (84/min), blood pressure 140/80. Edema 
of the lower legs and feet was noted. Chest X-ray (fig. 1) 
 visualized extensive merging areas of interstitial opacities 
or condensating in the lower and central portions of both 
lungs, and traces of fluid in the pleural cavity. Despite 
the heart contours obscured by a mediastinal shadow, the 
left ventricle was described as enlarged. The radiologi-
cal picture resembled that of ARDS. The aforementioned 
X-ray, as well as all subsequent ones, were performed 
using the same technique.
On a radiogram obtained a few days before in the Municipal 
Hospital, the picture of thoracic organs revealed no abnor-
malities. 
Laboratory tests still shared increased leukocytosis 
(WBC–32.5 g/l), anemia (Hb–9.59 g/dl), thrombocytopenia 
(PLT–35 g/l), decreased fibrinogen level and hyperglycemia. 
Bacteriological investigations (swabs from body cavities, 
blood and urine cultures) were negative. 
Figure 1.  Third day of hospitalization (ATRAS beginning). Extensive 
parenchymal infiltrates in both lungs. Pulmonary apices 
spared. Trace of fluid in the pleural cavities. Enlarged left 
ventricle. Radiological findings resemble ARDS.
72
© Pol J Radiol, 2007; 72(4): 70-73Case Report
The diagnosis of ATRAS was established. Vesanoid and 
daunorubicin were withdrawn. Corticosteroids (Dexa-
methasone) and oxygen therapy were instituted. Other 
medications were given in unchanged doses. The patient 
also received antibiotics (Augmentin, Aminkin) until the 
results of bacteriological investigations were obtained. 
Temperature reduction to the level below 37ºC was 
obtained, with a slight improvement of the patient’s general 
condition. X-ray performed on day 5 of hospitalization still 
revealed extensive density areas and increased amount of 
fluid in both pleural cavities (fig. 2). On the next days, the 
patient’s condition imporved gradually – the dyspnea and 
edema were reduced, and no new extravasations appeared. 
Crepitant rales over the lung fields were still present on 
auscultation. Laboratory tests revealed reduction of leuko-
cytosis (WBC–13 g/l). On day 7, another chest X-ray (fig. 3), 
revealed partial regression of interstitial abnormalities, 
total regression of exudate in the right pleural cavity and a 
small amount of fluid in the right pleural cavity, as well as 
normalization of heart size. 
On the subsequent days of hospitalization, the respiratory 
symptoms subsided gradually. However, the signs of hemor-
rhagic diathesis (extravasations) increased, and laboratory 
investigations revealed increased leukocytosis (on day 12, 
WBC 47.95g/l), aggravation of anemia and worsening of the 
coagulation system parameters. At that time (day 13), fur-
ther regression of pulmonary abnormalities was observed 
on chest X-ray – no densities in the lung fields and traces of 
fluid in the left pleural  cavity (fig. 4). 
Because of deterioration of symptoms of the underlying dise-
ase, it was decided to reintroduce daunorubicin and Vesanoid. 
Control chest X-ray performed on day 37 (fig. 5) revealed 
no pathologic changes. The patient remains in charge of the 
Hematology Department because of the underlying disease.
Discussion
As it follows from literature data, the signs of ATRAS have 
been observed mainly in the course of AML M3. The use of 
Figure 3.  Seventh day of hospitalization. Partial regression of 
parenchymal infiltrates. Complete regression of pleural 
effusion within the left pleuro-costal recess and trace of fluid 
within the right one. Heart shape – normal.
Figure 4.  Thirteenth day of hospitalization. Further regression – the 
lungs free from pathological changes, trace of fluid within the 
right pleural cavity. 
Figure 5.  Thirty seventh day of hospitalization. Normal chest X ray 
picture.
Figure 2.  Fifth day of hospitalization. Pulmonary consolidations still 
present. Amount of pleural effusion increased.
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ATRA in other forms of AML is still being tested in clini-
cal trials, and the reports concerning the development of 
ATRAS in the course of the disease are casuistic in character 
[14]. In a study by Frankel et al., the signs of the syndrome 
were observed in 25% of 35 treated patients [1]. According 
to Jung et al., the symptoms of ATRAS appeared in 22% of 
69 patients [7]. In a study by Botton et al., carried out in 
a larger group of patients, the incidence of the syndrome 
amounted to 15% [15].
The time of onset of ATRAS ranged from a few hours to 
 several dozen days after the institution of the therapy 
[1, 7, 15, 16, 17]. In the reported case, like in the studies 
by Botton et al. and Frankel et al. [1], the symptoms were 
observed starting from the second day of treatment. 
The predominant symptoms included the signs of respi-
ratory failure, increased body temperature and edema 
– observed most frequently also by other authors [1, 2, 3, 
7, 10, 13, 15]. No signs of renal failure, observed some-
times in the course of the syndrome [3, 7, 15], were noted 
in our patient. The patient demonstrated no clinical signs 
 indicating intrapulmonary hemorrhage, which can be 
observed at the later stages in more dramatic forms of the 
syndrome [2, 13, 18, 19].
A chest radiogram obtained on the first day of hospitali-
zation revealed cardiomegaly, merging density areas in 
the lungs and the present of fluid in the pleural cavities 
– which are relatively consistent radiological symptoms of 
ATRAS [1, 2, 3, 7, 12, 15]. The picture of lungs resembled 
that of ARDS. According to Jung et al., the picture of this 
type usually corresponds with progression of the syndrome 
and deterioration of the patient’s  clinical condition [7].
In differential diagnosis, Jung recommends consideration 
of cardiogenic pulmonary edema, ARDS, pulmonary lesions 
associated with the myeloproliferative process and pneu-
monia [7]. 
Although the lack of histopathological verification makes 
it impossible to determine unequivocally the charac-
ter of the changes observed in the reported case, nega-
tive  bacteriological results seem to exclude the infectious 
 etiology. Cardiogenic edema also seems unlikely in view 
of negative cardiovascular history, (except for mild hyper-
tension). Normal radiological findings before and after the 
regression of clinical symptoms, as well as regression of the 
observed changes after the withdrawal of ATRA and institu-
tion of standard treatment (corticosteroids) allow to exclude 
pulmonary abnormalities due to the  myeloproliferative 
 process. 
Conclusions
In view of lack of radiological features specific for ATRAS, 
changes of chest X-ray pictures in AML patients treated 
with ATRA require interpretation in clinical context.
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